StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)

Close on Nov 18, 2026Market cap $99.30MP/E –Yield –

Outlook Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Outlook Therapeutics's pe ratio was 3.1× on Jul 31, 2025.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jul 31, 20253.1×–

More Outlook Therapeutics figures

See a number that looks wrong?